BRCA Negative Study

Do You Have A Family History of Breast or Ovarian Cancer But You Or Someone In Your Family Tested Negative for BRCA1 or BRCA2?

Did you know that the KRAS-variant is an inherited gene mutation that explains over 50% of Hereditary Breast and Ovarian Cancer (HBOC) families with no other known genetic explanation?

If you or your family has been tested and is BRCA negative, you are eligible for our studies as well as for KRAS-variant testing. If you would like to join a study, please take the eligibility survey.

Take The Eligibility Survey

Stay up-to-date on the latest stories, events, news & research through our e-newsletter.

What we know about the KRAS-variant:

  • Found in 6-10% of the population. The KRAS-variant is up to 40x more common than BRCA mutations.
  • Explains the genetic cause of cancer for over 50% of Hereditary Breast and Ovarian Cancer (HBOC) families with no other known genetic markers.
  • Associated with advanced endometriosis and infertility.
  • Associated with a lifetime risk of breast cancer of > 20%, supporting eligibility for higher-level screening.
  • Associated primarily with post-menopausal ovarian cancer, enabling the opportunity for cancer prevention through informed decision making about ophorectomy (ovarian removal) at menopause.
  • Cancer is triggered by estrogen withdrawal, so important information to know before ovarian removal or menopause.

The KRAS-variant is a recently discovered, novel inherited genetic marker associated with cancer. The latest research indicates the KRAS-variant shows great potential to guide disease prevention and management across cancer types through its unique interactions with hormones and cancer therapies.


If you would like to join a study, please click the button below. You will be able to choose to get your KRAS-variant results at a discounted cost ($195) through the study.  If you would prefer to directly order KRAS-variant testing at cost ($295) without joining a study, please follow this link.

Take the Survey

MiraKind’s pipeline of planned and ongoing research studies are designed to protect the health of individuals with the KRAS-variant and to help answer the most pressing questions about cancer.

Research questions include:

  • What are the best cancer management strategies for KRAS-variant cancer patients?
  • What environmental factors, hormone exposures, medicines, or other lifestyle factors can influence cancer risk for individuals with the KRAS-variant?
  • How do individuals with the KRAS-variant respond differently to factors like hormone replacement therapy, birth control, or IVF?
  • How can cancer survivors who are positive for the KRAS-variant protect themselves from secondary cancers?
  • How can we prevent cancers associated with the KRAS-variant for family members who are positive but have never been diagnosed with cancer?
arrow up to top